^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
ET140203
i
Other names: ET140203, Autologous T cells transduced with lentivirus encoding an ET140203 expression construct, JWATM203, ET 140203, ET-140203, JWATM 203, JWATM-203
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Eureka Therap, JW (Cayman) Therap
Drug class:
Cytotoxic T lymphocyte stimulant, γδ TCR modulator, AFP inhibitor
Related drugs:
9ms
Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1) (clinicaltrials.gov)
P1/2, N=6, Terminated, Eureka Therapeutics Inc. | N=12 --> 6 | Trial completion date: Jun 2026 --> Jun 2023 | Recruiting --> Terminated | Trial primary completion date: Apr 2024 --> Jun 2023; Directing efforts to the pediatric study (ARYA-2) for this product
Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
|
AFP (Alpha-fetoprotein)
|
ET140203
10ms
Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1) (clinicaltrials.gov)
P1/2, N=12, Recruiting, Eureka Therapeutics Inc. | Phase classification: P2 --> P1/2 | Trial completion date: Jun 2024 --> Jun 2026 | Trial primary completion date: Jan 2024 --> Apr 2024
Phase classification • Trial completion date • Trial primary completion date • Metastases
|
AFP (Alpha-fetoprotein)
|
ET140203
2years
ARYA-2: ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma (clinicaltrials.gov)
P1/2, N=15, Recruiting, Eureka Therapeutics Inc. | N=25 --> 15 | Trial completion date: Feb 2026 --> Jan 2028 | Trial primary completion date: Feb 2024 --> Jan 2026
Enrollment change • Trial completion date • Trial primary completion date
|
AFP (Alpha-fetoprotein)
|
ET140203
2years
Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1) (clinicaltrials.gov)
P2, N=12, Recruiting, Eureka Therapeutics Inc. | N=50 --> 12 | Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Jan 2023 --> Jan 2024
Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
AFP (Alpha-fetoprotein)
|
ET140203
2years
ARYA-2: ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma (clinicaltrials.gov)
P1/2, N=25, Recruiting, Eureka Therapeutics Inc. | Trial completion date: Feb 2025 --> Feb 2026 | Trial primary completion date: Feb 2023 --> Feb 2024
Trial completion date • Trial primary completion date
|
AFP (Alpha-fetoprotein)
|
ET140203
Share via
